Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT)

Molecular Imaging and Biology

Volumn 12, Issue 5, 2010, Pages 488-499

  Kossodo, Sylvie ^a   Pickarski, Maureen ^b   Lin, Shu An ^b   Gleason, Alexa ^b   Gaspar, Renee ^b   Buono, Chiara ^a   Ho, Guojie ^a   Blusztajn, Agnieszka ^a   Cuneo, Garry ^a   Zhang, Jun ^a   Jensen, Jayme ^a   Hargreaves, Richard ^b   Coleman, Paul ^b   Hartman, George ^b   Rajopadhye, Milind ^a   Duong, Le Thi ^b   Sur, Cyrille ^b   Yared, Wael ^a   Peterson, Jeffrey ^a   Bednar, Bohumil ^b  

^a VisEn Medical Inc   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer; Integrin v 3; Near infrared fluorescence imaging; Optical tomography; Quantification

Indexed keywords

ALPHAVBETA5 INTEGRIN; BEVACIZUMAB; CATHEPSIN; FLUORESCENT DYE; INTEGRISENSE; PROTEINASE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER GROWTH; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG LABELING; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE MOLECULAR TOMOGRAPHY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NEAR INFRARED SPECTROSCOPY; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; FLUORESCENCE; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; PEPTIDE HYDROLASES; TISSUE DISTRIBUTION; TOMOGRAPHY; TRANSPLANTATION, HETEROLOGOUS;

EID: 78049350167     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0279-z     Document Type: Article

References (57)

1. E Ruoslahti 1996 RGD and other recognition sequences for integrins Annu Rev Cell Dev Biol 12 697 715 1:CAS:528:DyaK28XnsFClur0%3D 10.1146/annurev. cellbio.12.1.697 8970741 (Pubitemid 26422728)
2. X Lu D Lu MF Scully, et al. 2008 The role of integrin-mediated cell adhesion in atherosclerosis: pathophysiology and clinical opportunities Curr Pharm Des 14 2140 2158 1:CAS:528:DC%2BD1cXht1SntrfM 10.2174/138161208785740199 18781968
3. DG Stupack 2007 The biology of integrins Oncology 21 6 12 17927025
4. JD Hood DA Cheresh 2002 Role of integrins in cell invasion and migration Nat Rev Cancer 2 91 100 10.1038/nrc727 12635172
5. 5 in ocular neovascular diseases Proc Natl Acad Sci USA 93 9764 9769 1:CAS:528: DyaK28XlsFehsbs%3D 10.1073/pnas.93.18.9764 8790405 (Pubitemid 26296683)
6. 3 for angiogenesis Science 264 569 571 1:CAS:528:DyaK2cXjt1Sis7w%3D 10.1126/science.7512751 7512751
7. v3: a new prognostic indicator in breast cancer Clin Cancer Res 4 2625 2634 1:CAS:528:DyaK1cXns1Ogtb8%3D 9829725
8. v3 expression in colon carcinoma correlates with survival Mod Pathol 14 1126 1132 1:STN:280:DC%2BD3Mnltlaruw%3D%3D 10.1038/modpathol.3880447 11706074 (Pubitemid 33063206)
9. 3 Clin Cancer Res 6 3056 3061 1:CAS:528:DC%2BD3cXmsVOmsbo%3D 10955784
10. 3 integrin on tumor cells with a monoclonal antibody Abegrin™ Mol Cancer Ther 5 3122 3129 1:CAS:528:DC%2BD28XhtlagsbrF 10.1158/1535-7163.MCT-06-0356 17172415 (Pubitemid 46092054)
11. 5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors Ann Onc 18 1400 1407 1:STN:280:DC%2BD2svnsFSisQ%3D%3D 10.1093/annonc/mdm140 (Pubitemid 47305015)
12. R Haubner HJ Wester 2004 Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies Curr Pharm Des 10 1439 1455 1:CAS:528:DC%2BD2cXjsVykurg%3D 10.2174/1381612043384745 15134568 (Pubitemid 38559759)
13. I Dijkgraaf AJ Beer HJ Wester 2009 Application of RGD-containing peptides as imaging probes for alphavbeta3 expression Front Biosci 14 887 899 1:CAS:528:DC%2BD1MXltFejt7c%3D 10.2741/3284 19273106
14. 64Cu-labeled RGD peptide Bioconjug Chem 15 41 49 10.1021/bc0300403 14733582 (Pubitemid 38165979)
15. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis Nucl Med Biol 31 179 189 1:CAS:528:DC%2BD2cXhvVyht7g%3D 10.1016/j.nucmedbio.2003.10.002 15013483 (Pubitemid 38315112)
16. 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 1781 1785 1:CAS:528:DC%2BD3MXit1Ohtbk%3D 11280722
17. 3 integrin binding peptides in a nude mouse model Cancer Res 62 6146 6151 1:CAS:528:DC%2BD38XosF2ms7w%3D 12414640
18. TF Massoud SS Gambhir 2003 Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes & Dev 17 545 580 1:CAS:528:DC%2BD3sXisVejurY%3D 10.1101/gad.1047403 (Pubitemid 36307540)
19. v integrins Circulation 107 455 460 1:CAS:528: DC%2BD3sXks1eksQ%3D%3D 10.1161/01.CIR.0000044916.05919.8B 12551871 (Pubitemid 36158049)
20. 3 Circulation 108 336 341 10.1161/01.CIR.0000080326.15367.0C 12835208 (Pubitemid 36899026)
21. 3-targeted magnetic resonance imaging Nat Med 4 623 626 1:CAS:528:DyaK1cXjtFKgtr4%3D 10.1038/nm0598-623 9585240 (Pubitemid 28237365)
22. 3 in mice using multivalent or monovalent cRGD targeting vectors Mol Cancer 12 41 49 10.1186/1476-4598-6-41 (Pubitemid 47054426)
23. 3 expression with Cy7-labeled RGD multimers Mol Imaging Biol 8 226 236 10.1007/s11307-006-0041-8 16791749 (Pubitemid 44193419)
24. 3 in brain tumor xenografts Cancer Res 64 8009 8014 1:CAS:528:DC%2BD2cXptFels7Y%3D 10.1158/0008-5472.CAN-04-1956 15520209 (Pubitemid 39446936)
25. 3 expression in living mice Bioconjug Chem 16 1433 1441 1:CAS:528: DC%2BD2MXhtFGmtLjL 10.1021/bc0501698 16287239 (Pubitemid 41681509)
26. 3 in human tumor xenografts Mol Imaging 3 343 351 1:CAS:528:DC%2BD2MXitFymu7s%3D 10.1162/1535350042973481 15802051 (Pubitemid 40245456)
27. 3 in an orthotopic glioblastoma model Mol Imaging Biol 8 315 323 10.1007/s11307-006-0059-y 17053862 (Pubitemid 44741368)
28. W Cai K Chen ZB Li SS Gambhir X Chen 2007 Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature J Nucl Med 48 1862 1870 1:CAS:528:DC%2BD2sXhsVSitrzL 10.2967/jnumed.107.043216 17942800 (Pubitemid 350099333)
29. V Ntziachristos J Ripoll LV Wang R Weissleder 2005 Looking and listening to light: the evolution of whole-body photonic imaging Nat Biotechnol 23 313 320 1:CAS:528:DC%2BD2MXitF2nt7k%3D 10.1038/nbt1074 15765087 (Pubitemid 41094419)
30. EE Graves J Ripoll R Weissleder VA Ntziachristos 2003 Submillimeter resolution fluorescence molecular imaging system for small animal imaging Med Phys 30 901 911 1:CAS:528:DC%2BD3sXjtl2ksLo%3D 10.1118/1.1568977 12772999 (Pubitemid 36578694)
31. X Montet V Ntziachristos J Grimm R Weissleder 2005 Tomographic fluorescence mapping of tumor targets Cancer Res 65 6330 6336 1:CAS:528:DC%2BD2MXmt1egsbc%3D 10.1158/0008-5472.CAN-05-0382 16024635 (Pubitemid 40994419)
32. X Montet JL Figueiredo H Alencar V Ntziachristos U Mahmood R Weissleder 2007 Tomographic fluorescence of tumor vascular volume in mice Radiology 242 751 758 10.1148/radiol.2423052065 17325064
33. M Nahrendorf DE Sosnovik P Waterman, et al. 2007 Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct Circ Res 100 1218 1225 1:CAS:528:DC%2BD2sXktlOhs7c%3D 10.1161/01.RES.0000265064.46075.31 17379832 (Pubitemid 46684135)
34. J Kos TT Lah 1998 Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer Oncol Rep 5 1349 1361 1:CAS:528:DyaK1cXntFSrtrY%3D 9769367
35. 3 antagonists for the prevention and treatment of osteoporosis J Med Chem 47 4829 4837 1:CAS:528:DC%2BD2cXmvFChtbY%3D 10.1021/jm049874c 15369386 (Pubitemid 39238257)
36. J Wang MJ Breslin PJ Coleman, et al. 2004 Non-peptide αvβ3 antagonists. Part 7: 3-Substituted tetrahydro-[1, 8]naphthyridine derivatives Bioorg Med Chem Lett 14 1049 1052 1:CAS:528:DC%2BD2cXpvFejtQ%3D%3D 10.1016/j.bmcl.2003.11.036 15013021 (Pubitemid 38167640)
37. 1-mediated cell migration toward fibronectin J Biol Chem 272 29380 29389 1:CAS:528:DyaK2sXnsVOmsr0%3D 10.1074/jbc.272.46.29380 9361020 (Pubitemid 27498233)
38. U Landegren 1984 Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface. antigens J Immunol Methods 67 379 388 1:CAS:528:DyaL2cXhslaktL0%3D 10.1016/0022-1759(84)90477-0 6200537 (Pubitemid 14163018)
39. WL Rust SW Carper GE Plopper 2002 The promise of integrins as effective targets for anticancer agents J Biomed Biotech 2 124 130 1:CAS:528: DC%2BD3sXjt1yqtrs%3D 10.1155/S1110724302204015 (Pubitemid 44204508)
40. DA Reardon KL Fink T Mikkelsen, et al. 2008 Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Onc 26 5610 5617 1:CAS:528: DC%2BD1MXmsVSrsw%3D%3D 10.1200/JCO.2008.16.7510
41. CA Burnett J Xie J Quijano, et al. 2005 Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor Bioorg Med Chem 13 3763 3771 1:CAS:528: DC%2BD2MXjvVKltL8%3D 10.1016/j.bmc.2005.03.024 15863003 (Pubitemid 40615927)
42. S Achilefu S Bloch MA Markiewicz, et al. 2005 Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression Proc Natl Acad Sci USA 102 7976 7981 1:CAS:528:DC%2BD2MXkvF2ju7c%3D 10.1073/pnas.0503500102 15911748 (Pubitemid 40781048)
43. OH Aina J Marik R Gandour-Edwards KS Lam 2005 Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02" Mol Imaging 4 439 447 16285906
44. C Li W Wang Q Wu, et al. 2006 Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe Nucl Med Biol 33 349 358 1:CAS:528:DC%2BD28Xjs1Gktr8%3D 10.1016/j.nucmedbio.2006.01.001 16631083
45. JD Humphries A Byron MJ Humphries 2006 Integrin ligands at a glance J Cell Sci 119 3901 3903 1:CAS:528:DC%2BD2sXit1Cgsw%3D%3D 10.1242/jcs.03098 16988024 (Pubitemid 44650863)
46. X Montet M Funovics K Montet-Abou, et al. 2006 Multivalent effects of RGD peptides obtained by nanoparticle display J Med Chem 49 6087 6093 1:CAS:528:DC%2BD28XptFaitrw%3D 10.1021/jm060515m 17004722 (Pubitemid 44484952)
47. J Takagi BM Petre T Walz TA Springer 2002 Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling Cell 110 599 611 1:CAS:528:DC%2BD38XntlOhsbs%3D 10.1016/S0092-8674(02) 00935-2 12230977 (Pubitemid 35247840)
48. BD Adair J-P Xiong C Maddock SL Goodman MA Arnaout M Yeager 2005 Three-dimensional EM structure of the ectodomain of integrin alphaV-beta3 in a complex with fibronectin J Cell Biol 168 1109 1118 1:CAS:528: DC%2BD2MXivVGmsro%3D 10.1083/jcb.200410068 15795319
49. 3 in complex with an Arg-Gly-Asp ligand Science 296 151 155 1:CAS:528: DC%2BD38XivVWjsLo%3D 10.1126/science.1069040 11884718 (Pubitemid 34280076)
50. B Bednar ME Cunningham PA McQueney, et al. 1997 Flow cytometric measurement of kinetic and equilibrium binding parameters of arginine-glycine-aspartic acid ligands in binding to glycoprotein IIb/IIIa on platelets Cytometry 28 58 65 1:CAS:528:DyaK2sXjt1Glu7w%3D 10.1002/(SICI)1097- 0320(19970501)28:1<58::AID-CYTO7>3.0.CO;2-D 9136756 (Pubitemid 27208211)
51. 3 integrin promotes spontaneous metastasis of breast cancer to bone Breast Cancer Res 8 1 14 10.1186/bcr1398 (Pubitemid 44377911)
52. CR Cooper CH Chay KJ Pienta 2002 The role of alpha(v)beta(3) in prostate cancer progression Neoplasia 4 191 194 1:CAS:528:DC%2BD38XksFGnu74%3D 10.1038/sj.neo.7900224 11988838
53. SJ Bakewell P Nestor S Prasad, et al. 2003 Platelet and osteoclast beta3 integrins are critical for bone metastasis Proc Natl Acad Sci USA 100 14205 14210 1:CAS:528:DC%2BD3sXpsFGitbc%3D 10.1073/pnas.2234372100 14612570 (Pubitemid 37499215)
54. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 249 257 1:CAS:528:DC%2BD3cXmvVSls74%3D 10.1038/35025220 11001068
55. LG Presta H Chen SJ O'Connor, et al. 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599 1:CAS:528: DyaK2sXmslKqtLg%3D 9377574
56. MM Sadeghi S Krassilnikova J Zhang, et al. 2004 Detection of injury-induced vascular remodeling by targeting activated avb3 integrin in vivo Circulation 110 84 90 1:CAS:528:DC%2BD2cXlt1Sksr0%3D 10.1161/01.CIR.0000133319. 84326.70 15210600 (Pubitemid 38880138)
57. Bednar B, Lin SH, Gaspar R et al (2008) In vivo imaging detection of cathepsin activity and angiogenesis in mouse models of atherosclerosis. Abstract 2051 World Molecular Imaging Congress, Nice, France, September 10-14